Literature DB >> 22277730

High-frequency oscillatory ventilation after cardiac surgery: a treatment for all ages.

Ravi S Tripathi, Erica J Stein, Juan A Crestanello, Thomas J Papadimos.   

Abstract

Entities:  

Mesh:

Year:  2012        PMID: 22277730      PMCID: PMC3396232          DOI: 10.1186/cc10605

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.

In a recent issue of Critical Care, Bojan and colleagues [1] reported their experience with early initiation of high-frequency oscillatory ventilation (HFOV) in pediatric cardiac surgery that demonstrated shorter mechanical ventilation times and intensive care stays. Acute lung injury is common in adult patients undergoing surgery, yet there is scant reporting of the intraoperative utility of HFOV [2]. We initiated HFOV in a 49-year-old morbidly obese (body mass index of 69 kg/m2) man who had aortic stenosis, pulmonary hypertension, and decompensated congestive heart failure and who was undergoing aortic valve replacement. Separation from cardiopulmonary bypass (CPB) with inverse-ratio pressure-control ventilation - fraction of inspired oxygen (FiO2) of 1.0 and positive end-expiratory pressure (PEEP) of 18 cm H2O - failed because of hypoxia, defined as an arterial partial pressure of oxygen (PaO2) of 64 mm Hg. HFOV was initiated (mean pressure airway of 33 cm H2O and FiO2 of 1.0), yielding a PaO2 of 74 mm Hg and allowing CPB separation. The patient was transitioned to conventional ventilation on postoperative day 3 and was extubated on postoperative day 5. This adult patient benefited from HFOV, as did the pediatric population of Bojan and colleagues. Continuous positive intrathoracic pressure is a concern as it may impede venous return and thereby limit cardiac output (CO) [3]. However, the transition from ventilation with PEEP to HFOV usually results in significant changes in oxygenation/ventilation but not in CO [4]. In patients with pulmonary hypertension, HFOV has been demonstrated to increase CO and decrease pulmonary vascular resistance [5]. For our patient, HFOV allowed improved oxygenation without affecting hemodynamics. HFOV may be a safe and effective therapy to improve oxygenation/ventilation in patients undergoing cardiac surgery and possibly is underused because of unfounded hemodynamic concerns. HFOV needs exploration as a rescue tool after CPB for patients with hypoxia.

Abbreviations

CO: cardiac output; CPB: cardiopulmonary bypass; FiO2: fraction of inspired oxygen; HFOV: high-frequency oscillatory ventilation; PaO2: arterial partial pressure of oxygen; PEEP: positive end-expiratory pressure.

Competing interests

The authors declare that they have no competing interests.
  5 in total

1.  High-frequency jet ventilation improves cardiac function after the Fontan procedure.

Authors:  J N Meliones; E L Bove; M K Dekeon; J R Custer; F W Moler; L R Callow; N C Wilton; D B Rosen
Journal:  Circulation       Date:  1991-11       Impact factor: 29.690

2.  Anesthesia and intraoperative high-frequency oscillatory ventilation during burn surgery.

Authors:  Gautam Walia; George Jada; Robert Cartotto
Journal:  J Burn Care Res       Date:  2011 Jan-Feb       Impact factor: 1.845

Review 3.  High-frequency oscillatory ventilation (HFOV) and airway pressure release ventilation (APRV): a practical guide.

Authors:  S P Stawicki; Munish Goyal; Babak Sarani
Journal:  J Intensive Care Med       Date:  2009-07-17       Impact factor: 3.510

4.  Cardiovascular responses to high-frequency oscillatory ventilation during acute lung injury in sheep.

Authors:  Rikimaru Nakagawa; Tomonobu Koizumi; Koichi Ono; Kenji Tsushima; Sumiko Yoshikawa; Keishi Kubo; Tetutarou Otagiri
Journal:  J Anesth       Date:  2007-08-01       Impact factor: 2.078

5.  High-frequency oscillatory ventilation and short-term outcome in neonates and infants undergoing cardiac surgery: a propensity score analysis.

Authors:  Mirela Bojan; Simone Gioanni; Philippe Mauriat; Philippe Pouard
Journal:  Crit Care       Date:  2011-10-28       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.